20-21 November 2019 Jefferies 2019 London Healthcare Conference London, UK Team members attending: Dr Giuseppe Mazza, CEO, David Dally, CFO, Stephen Brindle, COO
This author has yet to write their bio.Meanwhile lets just say that we are proud primitus contributed a whooping 16 entries.
Entries by primitus
8-12 November 2019 70th Annual Meeting of the American Association for The Study of Liver Diseases (AASLD) Boston, USA Team members attending: Dr Giuseppe Mazza, CEO, Dr Gino Van Heeke, CSO, Massimo Pinzani
Golden Ticket includes one year of lab bench space at Cambridge, MA-based shared laboratory and office space London, UK, 5 November 2019 – Engitix Ltd (‘Engitix’), a private company focused on drug discovery for fibrosis and solid tumours based on its pioneering human extracellular matrix (ECM) platform, announced that its subsidiary Engitix, Inc, has been awarded a Golden Ticket […]
October 2019 Decellularized Human Gut as a Natural 3D Platform for Research in Intestinal Fibrosis Giuffrida. P, Curti. P, Al-Akkad. W, Biel. C, Crowley. C, Frenguelli. L, Telese. A, Hall. A, Tamburrino. D, Spolentini. G, Fusai. G, Tinozzi. FP, Pietrabissa. A, Corazza. GR, De Coppi. P, Pinzani. M, Di Sabatino. A, Rombouts. K, Mazza. G. […]
August 2019 Decellularized human liver scaffold-based three-dimensional culture system facilitate hepatitis B virus infection Zhang. Z, Xu. H, Mazza. G, Zhang. M, Frenguelli. L, Liu. Q, Al-Akkad. W, Ren. J, Zhao. R, Ren. F, Chen. X, Huang. A, Chen. J. Journal of Biomedical Materials Research Part A. 107(8):1744-1753.
June 2019 Donec ac efficitur purus at dignissim sapien Poster from Conference ABC
London, UK, 7 May 2019 – Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces the appointment of Gino Van Heeke, PhD, as Chief Scientific Officer (CSO), effective 7th May. Dr Van Heeke has over 20 years of […]
Nullam fermentum mi mauris Journal Of Praesent Eu Vapibus
February 2019 Vestibulum ante ipsum primis in faucibus Presentation from Conference XYZ
London, UK, 27 November 2018 – Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces it has closed a £5 million Series A financing, led by a private investor. Engitix has validated its proprietary tissue-specific and disease-specific human […]